The Northern Chinese province of Hebei, a leading region for pharmaceutical production, will offer excellent potential for pharma investment as it exits Covid-19 lockdown.

Hebei has always been among the top Chinese provinces for pharmaceutical manufacturing and, although in recent months production has been affected by the coronavirus, it contributes strong acquisition potential due to a substantial number of small companies operating in the area with a single facility. Read more here.